Effect of Salicylate on Glucose Metabolism in Insulin Resistance States
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00258128|
Recruitment Status : Completed
First Posted : November 24, 2005
Results First Posted : April 30, 2019
Last Update Posted : April 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Insulin Resistance||Drug: Salsalate Drug: Placebo||Phase 1 Phase 2|
Please see the following review articles on this topic:
Shoelson SE, Lee J, Goldfine AB. (2006) Inflammation in insulin resistance. J. Clin. Invest. 116, 1793-1801.
Goldfine AB, Fonseca V and Shoelson SE (2010) Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem. 57, 162-167.
Donath MY and Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 11, 98-107.
Goldfine AB and Shoelson SE (2017) Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 127, 83-93.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of Salicylate on Glucose Metabolism in Insulin Resistance States|
|Study Start Date :||January 2000|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||May 2008|
This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.
Other Name: Disalcid
Placebo Comparator: Placebo
This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.
Placebo for salslate, used only in the third trial
- Glucose [ Time Frame: 4 weeks ]fasting glucose
- Adiponectin [ Time Frame: 4 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00258128
|Principal Investigator:||Steven Shoelson||Joslin Diabetes Center|